TABLE 1.
Clinical and pathological features of sporadic EOCRC divided into three age groups
| Characteristic of EOCRC patients |
Group I 20‐29 years |
Group II 30‐39 years |
Group III 40‐49 years |
P‐value | Group I vs group II | Group I vs group III | Group II vs group III |
|---|---|---|---|---|---|---|---|
| Total number | 202 | 1196 | 4989 | ||||
| Gender | |||||||
| Male | 103 (51.0) | 569 (47.6) | 2470 (49.5) | 0.43 | |||
| Female | 99 (49.0) | 627 (52.4) | 2519 (50.5) | ||||
| Location | |||||||
| Colon | 133 (68.6) | 714 (61.0) | 2977 (61.0) | 0.10 | . | . | . |
| Rectum | 61 (31.4) | 456 (39.0) | 1905 (39.0) | ||||
| Mucinous histology | |||||||
| Absent | 188 (93.1) | 1126 (94.1) | 4741 (95.0) | 0.25 | |||
| Present | 14 (6.9) | 70 (5.9) | 248 (5.0) | ||||
| Signet‐ring cell histology | |||||||
| Absent | 191 (94.6) | 1152 (96.3) | 4919 (98.6) | <0.01 b | 0.23 | <0.01 | <0.01 |
| Present | 11 (5.4) | 44 (3.7) | 70 (1.4) | ||||
| Differentiation grade | |||||||
| Well/moderate | 108 (71.5) | 721 (79.7) | 3206(83.4) | <0.01 b | 0.02 | <0.01 | <0.01 |
| Poor | 43 (28.5) | 184 (20.3) | 636 (16.6) | ||||
| TNM stage | |||||||
| I | 30 (14.9) | 133 (11.1) | 668 (13.0) | 0.08 b | 0.13 | 0.55 | 0.04 |
| II | 12 (5.9) | 71 (5.9) | 238 (4.8) | 0.21 | |||
| III | 13 (6.4) | 118 (9.9) | 340 (6.8) | <0.01 b | 0.12 | 0.83 | <0.01 |
| IV | 26 (12.9) | 174(14.5) | 633 (12.7) | 0.23 | |||
| Number of metastasis | |||||||
| 0 | 146 (72.3) | 886 (74.1) | 3795 (76.1) | 0.19 | |||
| 1 | 35 (17.3) | 204 (17.1) | 745 (14.9) | 0.14 | |||
| 2 | 11 (5.4) | 71 (5.9) | 306 (6.1) | 0.90 | |||
| 3 | 9 (4.5) | 31 (2.6) | 130 (2.6) | 0.27 | |||
| Number of positive lymph nodes | |||||||
| <7 positive lymph nodes | 129 (83.8) | 816 (90.7) | 3599 (92.1) | <0.01 b | 0.01 | <0.01 | 0.16 |
| >7 positive lymph nodes | 25 (16.2) | 84 (9.3) | 307 (7.9) | ||||
| Lymphatic invasion a | |||||||
| No | 16 (66.7) | 67 (72.0) | 468 (79.7) | 0.09 b | 0.61 | 0.12 | 0.09 |
| Yes | 8 (33.3) | 26 (28.0) | 119 (20.3) | ||||
| Angioinvasion a | |||||||
| No | 14 (66.7) | 41 (69.5) | 331 (74.4) | 0.56 | |||
| Yes | 7 (33.3) | 18 (30.5) | 114 (25.6) | ||||
| KRAS mutation | |||||||
| Absent | 14 (58.3) | 72(63.2) | 261 (55.9) | 0.37 | |||
| Present | 10 (41.7) | 42 (36.8) | 206 (44.1) | ||||
| NRAS mutation | |||||||
| Absent | 13 (92.9) | 64(98.5) | 244 (94.6) | 0.38 | |||
| Present | 1(7.1) | 1 (1.5) | 14 (5.4) | ||||
| BRAF mutation | |||||||
| Absent | 18 (100) | 73 (93.6) | 299 (91.8) | 0.42 | |||
| Present | 0 (0) | 5 (6.4) | 26 (8.0) | ||||
a
Data of lymphatic invasion and angioinvasion was only available for years 2015 and 2016.
b
A two‐sided P‐value of less than 0.05 was considered statistically significant.